Heron Therapeutics (HRTX)
(Delayed Data from NSDQ)
$2.06 USD
+0.04 (1.98%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.06 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Cash flow Statements
Fiscal Year End for Heron Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -110.56 | -182.02 | -220.68 | -227.28 | -204.75 |
Depreciation/Amortization & Depletion | 1.50 | 2.36 | 4.26 | 4.40 | -0.64 |
Net Change from Assets/Liabilities | 16.79 | -10.51 | -35.08 | -13.01 | 29.23 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 33.48 | 43.26 | 48.15 | 51.07 | 51.57 |
Net Cash From Operating Activities | -58.79 | -146.91 | -203.35 | -184.82 | -124.58 |
Property & Equipment | -1.53 | -1.60 | -2.99 | -6.81 | -7.15 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 19.53 | -1.73 | 35.72 | 215.77 | -14.63 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 18.00 | -3.32 | 32.73 | 208.96 | -21.78 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 29.76 | 75.06 | 7.07 | 9.08 | 186.42 |
Issuance (Repayment) of Debt | 24.35 | 0.00 | 148.96 | 0.03 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 54.11 | 75.06 | 156.03 | 9.11 | 186.43 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 13.31 | -75.18 | -14.60 | 33.24 | 40.06 |
Cash at Beginning of Period | 15.36 | 90.54 | 105.14 | 71.90 | 31.84 |
Cash at End of Period | 28.68 | 15.36 | 90.54 | 105.14 | 71.90 |
Diluted Net EPS | -0.80 | -1.67 | -2.24 | -2.50 | -2.50 |
Fiscal Year End for Heron Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -12.40 | -3.16 | -110.56 | -99.84 | -74.83 |
Depreciation/Amortization & Depletion | 0.40 | 0.19 | 1.50 | 1.19 | 0.73 |
Net Change from Assets/Liabilities | -13.51 | -10.09 | 16.79 | 8.39 | -0.14 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 11.39 | 3.55 | 33.48 | 29.02 | 22.18 |
Net Cash From Operating Activities | -14.12 | -9.52 | -58.79 | -61.24 | -52.07 |
Property & Equipment | -0.64 | 0.00 | -1.53 | -1.30 | -0.50 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 3.96 | 1.28 | 19.53 | 28.13 | 50.55 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 3.33 | 1.28 | 18.00 | 26.83 | 50.05 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.50 | 0.01 | 29.76 | -0.20 | 0.11 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 24.35 | 24.35 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 29.76 | 0.00 |
Net Cash from Financing Activities | 0.50 | 0.01 | 54.11 | 53.91 | 0.11 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -10.29 | -8.23 | 13.31 | 19.50 | -1.90 |
Cash at Beginning of Period | 28.68 | 28.68 | 15.36 | 15.36 | 15.36 |
Cash at End of Period | 18.39 | 20.45 | 28.68 | 34.86 | 13.46 |
Diluted Net EPS | -0.06 | -0.02 | -0.01 | -0.17 | -0.35 |